Time filter

Source Type

News Article | February 16, 2017
Site: www.accesswire.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Akram H.,The National Hospital for Neurology and Neurosurgery | Allibone J.,The National Hospital for Neurology and Neurosurgery
Clinical Oncology | Year: 2010

Malignant spinal cord compression is an important neuro-oncological emergency, the management of which has been changing throughout the last 30 years. We hereby attempt to present an overview of this pathological entity with general management concepts, paying special attention to the palliative surgical treatments available, the decision-making process and the new emerging treatment modalities. © 2010 The Royal College of Radiologists.


Gleeson M.,The National Hospital for Neurology and Neurosurgery
Operative Techniques in Otolaryngology - Head and Neck Surgery | Year: 2016

The prerequisites for surgical resection of tumors arising in the jugular foramen are adequate access, control of the major vessels, and the ability to move the facial nerve safely of the operative field if necessary. Without it the surgeon risks catastrophic hemorrhage, cranial nerve palsies that might have been avoided, and insufficient access to remove the whole tumor. The aim of this article is to help the surgeon select the best approach for their patient and summarize the key steps in each. Consideration of a staged approach is prudent for paragangliomas that have significant intracranial extension, Fisch Di tumors. Paragangliomas confined to the temporal bone and intimately related to the internal carotid artery (ICA), Fisch C2-4, are better resected through a type A infratemporal fossa approach. Small jugular paragangliomas, Fisch C1, can be removed using a Fallopian bridge technique though limited rerouting of the facial nerve may sometimes be required. © 2016 Elsevier Inc.


Schott G.D.,The National Hospital for Neurology and Neurosurgery
Medical Humanities | Year: 2016

The term 'zoster' is nowadays associated with 'herpes zoster', the condition resulting from reactivation of the latent varicella-zoster virus which causes shingles. But in antiquity the meaning of 'zoster', a Latin word originating from the Greek for a belt or girdle, was variously associated in men with a form of body armour which could enclose just one half of the body; in women with a garment worn around the waist and sometimes called a 'zona'; and with a place, Zoster, linked mythologically then with the goddess Leto and her zona. Around 48 AD, the Roman physician Scribonius Largus became the first to associate 'zona' with 'herpes', and to attribute a medical meaning to 'zona', here an abbreviation of 'zona ignea' ('fiery girdle'). Although in the past the terms 'zoster' and 'zona' were sometimes used interchangeably, today only 'zoster' remains-even when etymologically illogical in those patients whose zoster rash occurs in body areas other than the trunk. © 2016 by the BMJ Publishing Group Ltd & Institute of Medical Ethics.


Lambru G.,The National Hospital for Neurology and Neurosurgery
Current pain and headache reports | Year: 2013

Primary headache disorders that are more frequently encountered in the paediatric population include migraine and tension-type headaches. The trigeminal autonomic cephalalgias (TACs), which includes cluster headache (CH), paroxysmal hemicrania (PH) and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), are rarely reported in the paediatric population. The 1-year prevalence of CH seems to be 0.03 %. The clinical features of childhood and adolescence onset CH seem to be similar to those of adult onset. Cranial autonomic features and restlessness seem to less prominent in children than in adults. When restlessness is present, it often manifests as thrashing around in children and can distract attention from the headache, thereby contributing to a delay in diagnosis. The frequency of cluster periods seems to be lower in childhood. Similarly, the duration of the single cluster period seems to be shorter. The temporal pattern shows a trend towards a gradual increase of frequency and duration of symptoms in adult life. In terms of management of paediatric CH, oxygen has been used successfully in several paediatric CH patients, and given its good side-effect profile, it is considered the abortive agent of choice for paediatric CH. Verapamil is the preventative drug of choice in both episodic and chronic CH, though paediatric patients should be started on lower doses and titrated according to age. Paediatric-onset PH and SUNCT are very rarely reported. The clinical phenotype and response to treatment seem to resemble the adult-onset form. Paediatric-onset TACs are poorly recognized and there is often a delay of several months or years before the diagnosis is made. Awareness of typical clinical pictures of these excruciating headaches is essential to allow prompt initiation of the appropriate management.


Schreiber B.E.,Royal Free Hampstead NHS Trust | Agrup C.,University College London | Haskard D.O.,Imperial College London | Luxon L.M.,The National Hospital for Neurology and Neurosurgery
The Lancet | Year: 2010

Sudden sensorineural hearing loss is usually unilateral and can be associated with tinnitus and vertigo. In most cases the cause is not identified, although various infective, vascular, and immune causes have been proposed. A careful examination is needed to exclude life threatening or treatable causes such as vascular events and malignant diseases, and patients should be referred urgently for further assessment. About half of patients completely recover, usually in about 2 weeks. Many treatments are used, including corticosteroids, antiviral drugs, and vasoactive and oxygen-based treatments. Although no treatment is proven, we recommend a short course of oral high-dose corticosteroids. There is much to learn about pathogenesis of sudden sensorineural hearing loss, and more clinical trials are needed to establish evidence-based management. © 2010 Elsevier Ltd. All rights reserved.


Keenan E.,The National Hospital for Neurology and Neurosurgery
Nursing times | Year: 2010

Specialist nurse roles appear to beunder threat in the UK and the role of the clinical nurse specialist has been subject to scrutiny recently. A trust developed a database so that data on the CNS workload and contribution to patient care could be collected and analysed. This showed the components of the role and the dear benefits to patient care.


Naidich T.P.,Mount Sinai School of Medicine | Naidich T.P.,Irving and Dorothy Regenstreif Research | Yousry T.A.,The National Hospital for Neurology and Neurosurgery
Medical Radiology | Year: 2015

We present the surface anatomy of the brain describing in detail the typical configuration of the sulci and gyri and their most frequent variations. After describing the borders of the lobes, we give guidance on the methods of localizing functionally important atomic structures such as the pericentral cortex, Heschl’s gyrus, and the calcarine sulcus. On the basis of the surface anatomy and the cytoarchi-tectonic subdivision of the cortex, we describe the function of selected areas related to the motor system and to speech. © Springer-Verlag Berlin Heidelberg 2015.


Lambru G.,The National Hospital for Neurology and Neurosurgery | Shanahan P.,The National Hospital for Neurology and Neurosurgery | Watkins L.,The National Hospital for Neurology and Neurosurgery | Matharu M.S.,The National Hospital for Neurology and Neurosurgery
Pain Physician | Year: 2014

Background: Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or with cranial autonomic symptoms (SUNA) are primary headaches characterized by frequent attacks of severe headaches in association with cranial autonomic features. Patients with chronic SUNCT or SUNA have unremitting symptoms that necessitate prolonged use of medical preventive treatments, many of which are prone to causing side effects. They can be medically intractable, in which case neurally destructive or cranially invasive surgical treatments can be offered, though these have hitherto yielded conflicting results. Occipital nerve stimulation (ONS) offers a nondestructive and relatively low risk surgical alternative. Objective: To assess the efficacy and safety of ONS in chronic, medically intractable SUNCT and SUNA patients. Study design: Prospective open-label study. Methods: Nine medically intractable, chronic SUNCT and SUNA patients were implanted with electrodes for bilateral occipital nerve stimulation. Data were collected prospectively for pre-and postimplantation headache characteristics, including frequency, intensity and duration of attacks. Diaries were used to assess headache improvement. Results: At a median follow-up of 38 months (range 24-55 months), all but one patient reported substantial improvement. Four patients became pain-free, 3 were almost pain-free (96-98% improvement), and one had a marked reduction in attack frequency and severity (81% improvement). After an initial rapid improvement, the maximum benefit of ONS was attained after a lag of a few months. Device malfunction was followed by recurrence or worsening of the attacks within a few days in most patients. Adverse events included lead migration, exposure of the electrode, and pain due to muscle recruitment over the leads. One patient developed hemicrania continua one month after implantation and was successfully treated with indomethacin. Conclusion: ONS appears to offer an effective and safe treatment option, without significant morbidity, for medically intractable SUNCT and SUNA. Given the variable results with cranially invasive or neurally destructive surgery, ONS might be considered the surgical treatment of choice for medically intractable SUNCT and SUNA.


News Article | February 16, 2017
Site: marketersmedia.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Loading The National Hospital for Neurology and Neurosurgery collaborators
Loading The National Hospital for Neurology and Neurosurgery collaborators